OncoMatch/Clinical Trials/NCT07124351

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

Is NCT07124351 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies CYTALUX™ (pafolacianine) for gastrointestinal cancer.

Phase 4RecruitingCedars-Sinai Medical CenterNCT07124351Data as of May 2026

Treatment: CYTALUX™ (pafolacianine) — This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Cedars-Sinai Medical Center · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify